“Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)”, J of Skin, vol. 5, no. 1, p. s3, Jan. 2021, doi: 10.25251/skin.5.supp.3.